Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome

Neurogastroenterology and Motility

Volumn 27, Issue 10, 2015, Pages 1354-1370

  Corsetti, M ^a   Akyuz, F ^a   Tack, J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Ibodutant; Nepadutant; NK1; NK2; NK3; Tachykinins

Indexed keywords

IBODUTANT; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR ANTAGONIST; TACHYKININ; TACHYKININ RECEPTOR; WATER;

CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DIGESTIVE SYSTEM FUNCTION DISORDER; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HUMAN; IMMUNOMODULATION; INFLAMMATION; INTESTINE MUSCLE; ION TRANSPORT; IRRITABLE COLON; MULTICENTER STUDY (TOPIC); NERVE CELL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WATER TRANSPORT; ANTAGONISTS AND INHIBITORS; GASTROINTESTINAL DISEASES; IRRITABLE BOWEL SYNDROME; PHYSIOLOGY;

GASTROINTESTINAL DISEASES; HUMANS; IRRITABLE BOWEL SYNDROME; RECEPTORS, TACHYKININ;

EID: 84942295980     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12616     Document Type: Review

References (116)

1. Holzer P, Holzer-Petsche U. Tachykinins in the gut. Part I. Expression, release and motor function. Pharmacol Ther 1997; 73: 173-217.
2. Shimizu Y, Matsuyama H, Shiina T, Takewaki T, Furness JB. Tachykinins and their functions in the gastrointestinal tract. Cell Mol Life Sci 2008; 65: 295-311.
3. Quartara L, Altamura M, Evangelista S, Maggi CA. Tachykinin receptor antagonists in clinical trials. Expert Opin Investig Drugs 2009; 18: 1843-64.
4. Patacchini R, Lecci A, Holzer P, Maggi CA. Newly discovered tachykinins raise new questions about their periheral roles and the tachykinin nomenclature. Trends Pharmacol Sci 2004; 25: 1-3.
5. Holzer P, Holzer-Petsche U. Tachykinin receptors in the gut: physiological and pathological implications. Curr Opin Pharmacol 2001; 1: 583-90.
6. Altamura M. Tachykinin NK2 receptor antagonists. A patent review (2006-2010). Expert Opin Ther Patents 2012; 22: 57-77.
7. Kurtz MM, Wang R, Clemens MK, Cascieri MA, Austin CP, Cunningham BR, Chicci GG, Liu Q. Identification, localization, and receptor characterization of novel mammaliam substance P-like peptides. Gene 2002; 296: 205-12.
8. Li H, Leeman SE, Slack BE, Hauser G, Saltsman WS, Krause JE, Blusztajn JK, Boyd ND. A substance P (neurokinin-1) receptor mutant carboxyl-terminally truncated to resemble a naturally occurring receptor isoform displays enhanced responsiveness and resistance to desensitization. Proc Natl Acad Sci U S A 1997; 94: 9475-80.
9. Bellucci F, Meini S, Catalioto RM, Catalani C, Giuliani S, Quartara L, Giolitti A, Faiella A et al. Pharmacological evaluation of alpha and beta human tachykinin NK(2) receptor splice variants expressed in CHO cells. Eur J Pharmacol 2004; 499: 229-38.
10. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-5.
11. Bensaid M, Faucheux BA, Hirsch E, Agid Y, Soubrié P, Oury-Donat F. Expression of tachykinin NK2 receptor mRNA in human brain. Neurosci Lett 2001; 303: 25-8.
12. Rigby M, O'Donnell R, Rupniak NM. Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain. J Comp Neurol 2005; 490: 335-53.
13. Jaafari N, Khomitch-Baud A, Christen MO, Jule Y. Distribution pattern of tachykinin NK2 receptors in human colon: involvement in the regulation of intestinal motility. J Comp Neurol 2007; 503: 381-91.
14. Jaafari N, Hua G, Adelaide J, Jule Y, Imbert J. Expression of the tachykinin receptor mRNAs in healthy human colon. Eur J Pharmacol 2008; 599: 121-5.
15. Jaafari N, Khomitch-Baud A, Gilhodes J-C, Hua G, Jule Y. Qualitative and quantitative analysis of tachykinin NK2 receptors in chemically defined human colonic neuronal pathways. J Comp Neurol 2008; 507: 1542-58.
16. Sternini C, Su D, Gamp PD, Bunnett NW. Cellular sites of expression of the neurokinin-1 receptor in the rat gastrointestinal tract. J Comp Neurol 1995; 358: 531-40.
17. Vannucchi MG, Faussone-Pellegrini MS. NK1, NK2 and NK3 tachykinin receptor localization and tachykinin distribution in the ileum of the mouse. Anat Embryol (Berl) 2000; 202: 247-55.
18. Grider JR. Tachykinins as transmitters of ascending contractile component of the peristaltic reflex. Am J Physiol 1989; 257(5 Pt 1): G709-14.
19. Saban R, Nguyen N, Saban MR, Gerard NP, Pasricha PJ. Nerve-mediated motility of ileal segments isolated from nk1 receptor knockout mice. Am J Physiol 1999; 277: G1173-9.
20. Patacchini R, Giuliani S, Turini A, Navarra G, Maggi CA. Effect of nepadutant at tachykinin NK2 receptors in human intestine and urinary bladder. Eur J Pharmacol 2000; 398: 389-97.
21. Nakamura A, Tanaka T, Imanishi A, Kawamoto M, Toyoda M, Mizojiri G, Tsukimi Y. Bidirectional regulation of human colonic smooth muscle contractility by tachykinin NK(2) receptors. J Pharmacol Sci 2011; 117: 106-15.
22. Cao W, Pricolo V, Zhang L, Behar J, Biancani P, Kirber MT. Gq-linked NK2 receptors mediate neutrally induced contraction of human sigmoid circular smooth muscle. Gastroenterology 2000; 119: 51-61.
23. Huber O, Bertrand C, Bunnet NW, Pellegrini CA, Nadel JA, Debas HT, Geppetti P. Tachykinins contract the circular muscle of the human esophageal body in vitro via NK2 receptors. Gastroenterology 1993; 105: 981-7.
24. Huber O, Bertrand C, Bunnet NW, Pellegrini CA, Nadel JA, Nakazato P, Debas HT, Geppetti P. Tachykinins mediate contraction of the human lower esophageal sphincther in vitro via activation of NK2 receptors. Eur J Pharmacol 1993; 239: 103-9.
25. Maggi CA, Patacchini R, Santicioli P, Giuliani S, Turini D, Barbanti G, Beneforti P, Misuri D et al. Human isolated small intestine: motor responses of the longitudinal muscle to field stimulation and exogenous neuropeptides. Naunyn Schmiedebergs Arch Pharmacol 1989; 339: 415-23.
26. Maggi CA, Patacchini R, Santicioli P, Giuliani S, Turini D, Barbanti G, Giachetti A, Meli A. Human isolated ileum: motor responses of the circular muscle to electrical field stimulation and exogenous neuropeptides. Naunyn Schmiedebergs Arch Pharmacol 1990; 341: 256-61.
27. Maggi CA, Giuliani S, Patacchini R, Santicioli P, Theodorsson E, Barbanti G, Turini D, Giachetti A. Tachykinin antagonists inhibit nerve-mediated contractions in the circular muscle of the human ileum. Involvement of neurokinin-2 receptors. Gastroenterology 1992; 102: 88-96.
28. Giuliani S, Barbanti G, Turini D, Quartara L, Rovero P, Giachetti A, Maggi CA. NK2 tachykinin receptors and contraction of circular muscle of the human colon: characterization of the NK2 receptor subtype. Eur J Pharmacol 1991; 203: 365-70.
29. Kolbel CB, Mayer EA, Holtmann G, Layer P, Petschulat W, Erhard J. Effects of neurokinins on human colonic motility. Neurogastroenterol Motil 1994; 6: 119-27.
30. Burcher E, Shang E, Warner FJ, Du Q, Lubowski DZ, King DW, Liu L. Tachykinin NK2 receptors and functional mechanisms in human colon: changes with indomethacin and in diverticular disease and ulcerative colitis. J Pharmacol Exp Ther 2008; 324: 170-8.
31. Brierley SM, Nichols K, Grasby DJ, Waterman SA. Neural mechanisms underlying migrating motor complex formation in mouse isolated colon. Br J Pharmacol 2001; 132: 507-17.
32. Mule F, D'Angelo S, Tabacchi G, Serio R. Involvement of tachykinin NK2 receptors in the modulation of spontaneous motility in rat proximal colon. Neurogastronterol Motil 2000; 12: 459-66.
33. Cao W, Harnett KM, Pricolo VE. Nk2 receptor-mediated spontaneous phasic contractions in normal and ulcerative colitis human sigmoid colon. J Pharmacol Exp Ther 2006; 317: 1349-55.
34. Mule F, Amato A, Vannucchi MG, Faussone-Pellegrini MS, Serio R. Altered tachykinergic influence on gastric mechanical activity in mdx mice. Neurogastroenterol Motil 2006; 18: 844-52.
35. Maggi C, Giuliani S. Evidence that tachykin NK2 receptors modulate resting tone in the rat isolated small intestine. Br J Pharmacol 1996; 118: 1262-8.
36. Holzer P, Maggi CA. Sinergistic role of muscarinic acetylcholine and tachykinin NK2 receptors in intestinal peristalsis. Naunyn Schmiedeberg's Arch Pharmacol 1994; 349: 194-201.
37. Holzer P, Lippe IT, Heinemann A, Barthó L. Tachykinin NK1 and NK2 receptor-mediated control of peristaltic propulsion in the guinea-pig small intestine in vitro. Neuropharmacology 1998; 37: 131-8.
38. Bartho L, Holzer P, Leander S, Lembeck F. Evidence for an involvement of substance P, but not cholecystokinin-like peptides, in hexamethonium-resistant intestinal peristalsis. Neuroscience 1989; 28: 211-7.
39. Tonini M, Spelta V, De Ponti F, De Giorgio R, D'Agostino G, Stanghellini V, Corinaldesi R, Sternini C et al. Tachykinin-dependent and -independent components of peristalsis in the guinea pig isolated distal colon. Gastroenterology 2001; 120: 938-45.
40. Sanger GJ, Tuladhar BR, Brown J, Aziz E, Sivakumar D, Furness JB. Modulation of peristalsis by NK3 receptor antagonism in guinea-pig isolated ileum is revealed as intraluminal pressure is raised. Auton Autacoid Pharmacol 2007; 27: 105-11.
41. Onori L, Aggio A, Taddei G, Tonini M. Contribution of NK(2) tachykinin receptors to propulsion in the rabbit distal colon. Am J Physiol Gastrointest Liver Physiol 2000; 278: G137-47.
42. Onori L, Aggio A, Taddei G, Ciccocioppo R, Severi C, Carnicelli V, Tonini M. Contribution of NK3 tachykinin receptors to propulsion in the rabbit isolated distal colon. Neurogastroenterol Motil 2001; 13: 211-9.
43. Onori L, Aggio A, Taddei G, Loreto MF, Ciccocioppo R, Vicini R, Tonini M. Peristalsis regulation by tachykinin NK1 receptors in the rabbit isolated distal colon. Am J Physiol Gastrointest Liver Physiol 2003; 285: G325-31.
44. Deiteren A, De Winter BY, Nullens S, Pelckmans PA, De Man JG. Role of tachykinin receptors in the modulation of colonic peristaltic activity in mice. Eur J Pharmacol 2011; 667: 339-47.
45. Perdue MH, Galbraith R, Davison JS. Evidence for substance P as a functional neurotransmitter in guinea pig small intestinal mucosa. Regul Pept 1987; 18: 63-74.
46. Mantyh CR, Vigna SR, Maggio JE, Mantyh PW, Bollinger RR, Pappas TN. Substance P binding sites on intestinal lymphoid aggregates and blood vessels in inflammatory bowel disease correspond to authentic NK-1 receptors. Neurosci Lett 1994; 178: 255-9.
47. Fiebich BL, Schleicher S, Butcher RD, Craig A, Lieb K. The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-kappa B. J Immunol 2000; 165: 5606-11.
48. Laurenzi MA, Persson MA, Dalsgaard CJ, Haegerstrand A. The neuropeptide substance P stimulates production of interleukin 1 in human blood monocytes: activated cells are preferentially influenced by the neuropeptide. Scand J Immunol 1990; 31: 529-33.
49. Lieb K, Fiebich BL, Busse-Grawitz M, Hüll M, Berger M, Bauer J. Effects of substance P and selected other neuropeptides on the synthesis of interleukin-1 beta and interleukin-6 in human monocytes: a re-examination. J Neuroimmunol 1996; 67: 77-81.
50. Simeonidis S, Castagliuolo I, Pan A, Liu J, Wang CC, Mykoniatis A, Pasha A, Valenick L et al. Regulation of the NK-1 receptor gene expression in human macrophage cells via an NF-kappa B site on its promoter. Proc Natl Acad Sci U S A 2003; 100: 2957-62.
51. Maifrino LB, Liberti EA, de Souza RR. Vasoactive-intestinal-peptide- and substance-P-immunoreactive nerve fibres in the myenteric plexus of mouse colon during the chronic phase of Trypanosoma cruzi infection. Ann Trop Med Parasitol 1999; 93: 49-56.
52. Depoortere I, Thijs T, Thielemans L, Keith JC, Van Assche G, Peeters TL. Effect of recombinant human interleukin-11 on motilin and substance P release in normal and inflamed rabbits. Regul Pept 2001; 97: 111-9.
53. Traub RJ, Hutchcroft K, Gebhart GF. The peptide content of colonic afferents decreases following colonic inflammation. Peptides 1999; 20: 267-73.
54. Höckerfelt U, Franzén L, Kjörell U, Forsgren S. Parallel increase in substance P and VIP in rat duodenum in response to irradiation. Peptides 2000; 21: 271-81.
55. Lecci A, Capriati A, Altamura M, Maggi CA. Tachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human. Auton Neurosci 2006; 126-127: 232-49.
56. Höckerfelt U, Franzén L, Norrgård O, Forsgren S. Early increase and later decrease in VIP and substance P nerve fiber densities following abdominal radiotherapy: a study on the human colon. Int J Radiat Biol 2002; 78: 1045-53.
57. Stucchi AF, Shofer S, Leeman S, Materne O, Beer E, McClung J, Shebani K, Moore F et al. NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. Am J Physiol Gastrointest Liver Physiol 2000; 279: G1298-306.
58. Grady EF, Yoshimi SK, Maa J, Valeroso D, Vartanian RK, Rahim S, Kim EH, Gerard C et al. Substance P mediates inflammatory oedema in acute pancreatitis via activation of the neurokinin-1 receptor in rats and mice. Br J Pharmacol 2000; 130: 505-12.
59. Cutrufo C, Evangelista S, Cirillo R, Ciucci A, Conte B, Lopez G, Manzini S, Maggi CA. Effect of MEN 11467, a new tachykinin NK1 receptor antagonist, in acute rectocolitis induced by acetic acid in guinea-pigs. Eur J Pharmacol 1999; 374: 277-83.
60. Cutrufo C, Evangelista S, Cirillo R, Ciucci A, Conte B, Lopez G, Manzini S, Maggi CA. Protective effect of the tachykinin NK2 receptor antagonist nepadutant in acute rectocolitis induced by diluted acetic acid in guinea-pigs. Neuropeptides. 2000; 34: 355-9.
61. Fargeas MJ, Fioramonti J, Bueno L. Involvement of capsaicin-sensitive afferent nerves in the intestinal motor alterations induced by intestinal anaphylaxis in rats. Int Arch Allergy Immunol 1993; 101: 190-5.
62. Castex N, Fioramonti J, Fargeas MJ, More J, Bueno L. Role of 5-HT3 receptors and afferent fibers in the effects of mast cell degranulation on colonic motility in rats. Gastroenterology 1994; 107: 976-84.
63. Toulouse M, Fioramonti J, Maggi C, Bueno L. Role of NK2 receptors in gastric barosensitivity and in experimental ileus in rats. Neurogastroenterol Motil 2001; 13: 45-53.
64. Ciechanownicz R, Sein-Anand J, Chodorowski Z, Bitel M, Petrusewicz J, Korolkiewicz RP. Salutary effects of tachykinin receptor antagonists in a rat model of postoperative ileus. J Surg Res 2006; 133: 197-202.
65. Menzies JR, McKee R, Corbett AD. Differential alterations in tachykinin NK2 receptors in isolated colonic circular smooth muscle in inflammatory bowel disease and idiopathic chronic constipation. Regul Pept 2001; 99: 151-6.
66. Smith AS, Smid SD. Impaired capsaicin and neurokinin-evoked colonic motility in inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20: 697-704.
67. Liu L, Shang F, Markus I, Burcher E. Roles of substance P receptors in human colon circular muscle: alterations in diverticular disease. J Pharmacol Exp Ther 2002; 302: 627-35.
68. Mantyh CR, Pappas TN, Lapp JA, Washington MK, Neville LM, Ghilardi JR, Rogers SD, Mantyh PW et al. Substance P activation of enteric neurons in response to intraluminal Clostridium difficile toxin A in the rat ileum. Gastroenterology 1996; 111: 1272-80.
69. Koon HW, Pothoulakis C. Immunomodulatory properties of substance P: the gastrointestinal system as a model. Ann N Y Acad Sci 2006; 1088: 23-40.
70. Castagliuolo I, Riegler M, Pasha A, Nikulasson S, Lu B, Gerard C, Gerard NP, Pothoulakis C. Neurokinin-1 (NK-1) receptor is required in Clostridium difficile- induced enteritis. J Clin Invest. 1998; 101: 1547-50.
71. Ikeda K, Miyata K, Orita A, Kubota H, Yamada T, Tomioka K. RP67580, a neurokinin1 receptor antagonist, decreased restraint stress-induced defecation in rat. Neurosci Lett 1995; 198: 103-6.
72. Julia V, Morteau O, Bueno L. Involvement of neurokinin 1 and 2 receptors in viscerosensitive response to rectal distension in rats. Gastroenterology 1994; 107: 94-102.
73. Holzer-Petsche U, Rordorf-Nikolić T. Central versus peripheral site of action of the tachykinin NK1-antagonist RP 67580 in inhibiting chemonociception. Br J Pharmacol 1995; 115: 486-90.
74. Lu CL, Pasricha PJ, Hsieh JC, Lu RH, Lai CR, Wu LL, Chang FY, Lee SD. Changes of the neuropeptides content and gene expression in spinal cord and dorsal root ganglion after noxious colorectal distension. Regul Pept 2005; 131: 66-73.
75. Greenwood-Van Meerveld B, Gibson MS, Johnson AC, Venkova K, Sutkowski-Markmann D. NK1 receptor-mediated mechanisms regulate colonic hypersensitivity in the guinea pig. Pharmacol Biochem Behav 2003; 74: 1005-13.
76. Okano S, Nagaya H, Ikeura Y, Natsugari H, Inatomi N. Effects of TAK-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo. J Pharmacol Exp Ther 2001; 298: 559-64.
77. Gaudreau GA, Plourde V. Role of tachykinin NK1, NK2 and NK3 receptors in the modulation of visceral hypersensitivity in the rat. Neurosci Lett 2003; 351: 59-62.
78. Fioramonti J, Gaultier E, Toulouse M, Sanger GJ, Bueno L. Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action. Neurogastroenterol Motil 2003; 15: 363-9.
79. Shafton AD, Bogeski G, Kitchener PD, Lewis VA, Sanger GJ, Furness JB. Effects of the peripherally acting NK receptor antagonist, SB-235375, on intestinal and somatic nociceptive responses and on intestinal motility in anaesthetized rats. Neurogastroenterol Motil 2004; 16: 223-31.
80. Laird JM, Olivar T, Roza C, De Felipe C, Hunt SP, Cervero F. Deficits in visceral pain and hyperalgesia of mice with a disruption of the tachykinin NK1 receptor gene. Neuroscience 2000; 98: 345-52.
81. Toulouse M, Coelho AM, Fioramonti J, Lecci A, Maggi C, Bueno L. Role of tachykinin NK2 receptors in normal and altered rectal sensitivity in rats. Br J Pharmacol 2000; 129: 193-9.
82. Kamp EH, Beck DR, Gebhart GF. Combinations of neurokinin receptor antagonists reduce visceral hyperalgesia. J Pharmacol Exp Ther 2001; 299: 105-13.
83. McLean PG, Picard C, Garcia-Villar R, Moré J, Fioramonti J, Buéno L. Effects of nematode infection on sensitivity to intestinal distension: role of tachykinin NK2 receptors. Eur J Pharmacol 1997; 337: 279-82.
84. Bernstein CN, Robert ME, Eysselein VE. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. Am J Gastroenterol 1993; 88: 908-13.
85. Watanabe T, Kubota Y, Muto T. Substance P containing nerve fibers in ulcerative colitis. Int J Colorectal Dis 1998; 13: 61-7.
86. Neunlist M, Aubert P, Toquet C, Oreshkova T, Barouk J, Lehur PA, Schemann M, Galmiche JP. Changes in chemical coding of myenteric neurones in ulcerative colitis. Gut 2003; 52: 84-90.
87. Mönnikes H, van der Voort IR, Wollenberg B, Heymann-Monnikes I, Tebbe JJ, Alt W, Arnold R, Klapp BF et al. Gastric perception thresholds are low and sensory neuropeptide levels high in Helicobacter pylori-positive functional dyspepsia. Digestion. 2005; 71: 111-23.
88. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53: 1096-101.
89. Dong WZ, Zou DW, Li ZS, Zou XP, Zhu AY, Xu GM, Yin N, Gong YF et al. Study of visceral hypersensitivity in irritable bowel syndrome. Chin J Dig Dis. 2004; 5: 103-9.
90. Palsson OS, Morteau O, Bozymski EM, Woosley JT, Sartor RB, Davies MJ, Johnson DA, Turner MJ et al. Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. Dig Dis Sci 2004; 49: 1236-43.
91. Simrén M, Stotzer PO, Sjövall H, Abrahamsson H, Björnsson ES. Abnormal levels of neuropeptide Y and peptide YY in the colon in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2003; 15: 55-62.
92. Mitolo-Chieppa D, Mansi G, Nacci C, De Salvia MA, Montagnani M, Potenza MA, Rinaldi R, Lerro G et al. Idiopathic chronic constipation: tachykinins as cotransmitters in colonic contraction. Eur J Clin Invest 2001; 31: 349-55.
93. Tattersall FD, Rycroft W, Francis B, Pearce D, Merchant K, MacLeod AM, Ladduwahetty T, Keown L et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 1996; 35: 1121-9.
94. Akyuz F, Mimidis K, Nikolai H, Vos R, Tack J. Influence of NK1 receptor antagonist aprepitant on rectal sensitivity and compliance in healthy volunteers. Gastroenterology 2007; 32(Suppl. 2): A-684.
95. Lee OY, Munakata J, Naliboff BD, Chang I, Mayer EA. A double-blind parallel group pilot study of the effect of CJ-11, 974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. Gastroenterology 2000; 118: A-846.
96. Tillisch K, Labus J, Nam B, Bueller J, Smith S, Suyenobu B, Siffert J, McKelvy J et al. Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study. Aliment Pharmacol Ther 2012; 35: 360-7.
97. Madsen JL, Fuglsang S. A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans. Aliment Pharmacol Ther 2008; 27: 609-15.
98. Ang D, Pauwels A, Akyuz F, Vos R, Tack J. Influence of a neurokinin-1 receptor antagonist (aprepitant) on gastric sensorimotor function in healthy volunteers. Neurogastroenterol Motil 2013; 25: e830-8.
99. Willert RP, Hobson AR, Delaney C, Hicks KJ, Dewit OE, Aziz Q. Neurokinin-1 receptor antagonism in a human model of visceral hypersensitivity. Aliment Pharmacol Ther 2007; 25: 309-16.
100. Jocic M, Schuligoi R, Schöninkle E, Pabst MA, Holzer P. Cooperation of NMDA and tachykinin NK(1) and NK(2) receptors in the medullary transmission of vagal afferent input from the acid-threatened rat stomach. Pain 2001; 89: 147-57.
101. Houghton LA, Cremonini F, Camilleri M, Busciglio I, Fell C, Cox V, Alpers DH, Dewit OE et al. Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol Motil 2007; 19: 732-43.
102. Dukes GE, Dewit OE, Sanger GJ, Ameen VZ, Northcutt AR, Perschy TL, Schmith GD, Hamedani AG et al. Lack of effect of the Nk3 receptor antagonist, talnetant SB223242, on symptoms of IBS: results of 2 randomised, double blind, placebo-controlled dose ranging trials. Gastroenterology 2007; 132: A-60.
103. Lordal M, Navalesi G, Theodorsson E, Maggi CA, Hellstrom PM. A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br J Pharmacol 2001; 134: 215-23.
104. Delvaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut 2002; 51: 57-61.
105. Lecci A, Altamura M, Capriati A, Maggi CA. Tachykinin receptors and gastrointestinal motility: focus on humans. Eur Rev Med Pharmacol Sci 2008; 12 (Suppl. 1): 69-80.
106. Cialdai C, Tramontana M, Patacchini R, Lecci A, Catalani C, Catalioto RM, Meini S, Valenti C et al. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist. Eur J Pharmacol 2006; 549: 140-8.
107. www.clinicaltrials.gov. NCT00761007, NCT 01303224, NCT 02107196, NCT 02120027
108. Tack J, Madami A, Scartoni S, Ott K, Ligas F, Capriati A, Maggi A. Weekly assessment of satisfactory relief vs. quantitative daily assessment of signs and symptoms in IBS: do they provide comparable data? The IRIS-2 study experience with ibodutant in IBS-D. Gastroenterology 2013; 144: S-565-6.
109. Corsetti M, Tack J. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol Motil 2013; 25: 453-7.
110. www.clinicaltrials.gov. NCT01258153 and NCT01532518.
111. Koletzko S, Baltserovich N, Shcherbina A, Galustyan A, Bertolotti M, Zinzi D, Poggiali G, Scartoni S et al. A randomised, double-blind, placebo-controlled Phase II study to evaluate the efficacy of 7 days of orally administered nepadutant in infants with colic - the NO-CRY study. Gastroenterology 2015; 148: S423.
112. Zakko S, Barton G, Weber E, Dunger-Baldauf C, Rühl A. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011; 33: 1311-21.
113. Camilleri M. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome. Expert Opin Pharmacother 2013; 14: 1151-60.
114. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 1350-65.
115. Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology 2013; 145: 329-38.e1.
116. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL et al. TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.